Just weeks ago, we said one of the most oversold pharmaceutical stocks to buy for the long haul was AbbVie (SYM: ABBV). In fact, on January 14, the pharmaceutical giant was trading at about $172. Today, it’s up to $206.51 and could easily race higher.
|
Company: AbbVie (SYM: ABBV) Even better, the company just declared a $1.64 quarterly dividend, which is payable on May 15 to shareholders of record as of April 15. |
Investors Alley
What Elon Musk doesn’t want investors to know
There’s a little-known secret about Tesla that even seasoned investors don’t know. Despite not paying a traditional dividend, there’s a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
Click here to uncover Tesla’s hidden income secret.
|
AbbVie said it generated $15.1 billion in sales and an adjusted profit of $2.16 a share. Sales, up 5.6% year over beat, beat forecasts for $14.83 billion. And while earnings sank 23%, they still topped expectations for $2.12. “Importantly, AbbVie’s immunological powerhouses, Skyrizi and Rinvoq, generated a respective $3.78 billion and $1.83 billion in sales. Skyrizi revenue rocketed nearly 58% vs. the year-earlier period, while Rinvoq sales jumped more than 46%. Both beat expectations and helped offset a sales miss for Humira,” added Investor’s Business Daily. |
Mode Mobile
Data monetization shoots AI stock past $2B – is Mode next?
BigBear.ai’s stock surged 412% in three months on AI and data plays for government agencies.
But Mode Mobile helps consumers make money on their own data just by using your phone like you normally do.
So when you use apps…Listen to music…Or just charge your phone…You can get paid.
So while BigBear.ai helps the rich get richer, Mode is positioned to capitalize on the biggest trend in tech: user data value.
The company has just locked in their Nasdaq ticker ($MODE) as the data revolution accelerates, but pre-IPO shares are still available at just $0.26 each (plus 100% bonus shares when you act today).
Mode’s users have already saved and earned $325M+, and with partnerships with Walmart and Best Buy, the company looks to be just getting started.
Don’t miss out: Pre-IPO shares available at $0.26 with 100% bonus shares for early investors.
|
Guidance wasn’t too shabby either. For full-year 2025. The company expects to post EPS of between $12.12 and $12.32, as compared to estimates of $12.13. Plus, according to ABBV CEO Robert Michael: “2024 was a year of significant progress for AbbVie. Our growth platform delivered outstanding results, we advanced our pipeline with key regulatory approvals and promising data, and we strengthened our business through strategic transactions. We are entering 2025 with significant momentum and expect net revenues to exceed their previous peak in just the second full year following the U.S. Humira loss of exclusivity.” In short, ABBV offers significant upside potential moving forward. |
Brownstone Research
Media Is Mocking Elon, But Wait Until They Watch This Demo…
Elon Musk believes his new AI product will be worth an incredible $9 trillion.
But the mainstream media is not buying it…
Fortune called it “all smoke and mirrors”, and The Economist said that Elon’s promises are “long on bombast and short on reality.”
Who is right?
Elon or the Media?
